Publicaciones archivadas
....................................................................................................................................................................................
Estas publicaciones acerca de Oculus Incorporated están ordenadas por fecha, desde la más reciente a la más antigua. Necesitará Adobe® Reader®, un programa gratuito, para ver los documentos en PDF. 2008
March 28, 2008
Oculus
Innovative Sciences, Inc., Announces $13.9 Million
Securities Offering
March 27, 2008
Oculus
Innovative Sciences Receives Chinese SFDA Regulatory
Approval of Microcyn® Technology
March 17, 2008
Oculus
Innovative Sciences Announces Positive Results From
Three Abstracts Evaluating the Use of Microcyn® Technology
in Diabetic Foot Ulcers
March 14, 2008
Oculus
Innovative Sciences Announces Additional Phase II
Data for Microcyn® Technology in Mildly Infected
Diabetic Foot Ulcers
March 12, 2008
Oculus
Innovative Sciences Announces Acceptance of Three
Abstracts on the use of Microcyn® Technology
in Diabetic Foot Ulcers by DFCon 08
March 11, 2008
Oculus
Innovative Sciences to Announce Additional Phase
II Data and Data from Two Recent International Studies
at DFCon 08
February 27, 2008
Oculus
Innovative Sciences Schedules Conference Call Today
to Discuss Positive Top-Line Phase II Data with Microcyn® Technology
in Mildly Infected Diabetic Foot Ulcers
February 27, 2008
Oculus
Innovative Sciences Announces Positive Top-Line Phase
II Data with Microcyn® Technology in Mildly Infected
Diabetic Foot Ulcers
February 14, 2008
Oculus
Innovative Sciences to Present at the Roth Capital
Partners 20th Annual OC Growth Stock Conference
February 7, 2008
Oculus
Innovative Sciences Announces Fiscal Third Quarter
2008 Quarterly Results and Clinical Update
February 5, 2008
Oculus
Schedules Fiscal Third Quarter 2008 Financial Results
Release and Conference Call
January 29, 2008
Oculus
Innovative Sciences Announces Agreement with Animal
Health International for North American Distribution
of Microcyn®-Based Vetericyn™ Wound Spray
January 24, 2008
Oculus
Innovative Sciences Awarded Damages by Federal Court
in Intellectual Property Rights Litigation
January 22, 2008
Top-Line
Data from Oculus Innovative Sciences' Phase II Trial
to Be Presented at DFCon 08 (Diabetic Foot Global
Conference) on March 14, 2008
January 17, 2008
Oculus
Innovative Sciences, Inc. Appoints Gregg Alton to
its Board of Directors
January 3, 2008
Oculus
Innovative Sciences Completes Patient Treatment and
Follow-up in Its Phase II Clinical Trial in Mildly
Infected Diabetic Foot Ulcers
2007
December 18, 2007
Oculus
Innovative Sciences Announces Completion of Two Randomized
Controlled Clinical Trials of Microcyn® Technology
in China
December 5, 2007
Oculus
Innovative Sciences Completes Enrollment of Phase
II Trial of Microcyn® Technology in Treatment
of Mildly Infected Diabetic Foot Ulcers
November 19, 2007
Oculus
Innovative Sciences Wins Federal Court Ruling in
Intellectual Property Rights Litigation
November 12, 2007
Oculus
Innovative Sciences Announces Fiscal Second Quarter
2008 Quarterly Results and Clinical Update
November 8, 2007
Oculus
Innovative Sciences Schedules Fiscal Second Quarter
2008 Financial Results Release and Conference Call
November 1, 2007
Oculus
Innovative Sciences to Present at SMH Capital Markets
Investor Growth Conference
October 30, 2007
Oculus
Innovative Sciences to Present at Acumen BioFin 9th
Annual Healthcare Conference
October 3, 2007
Oculus
Innovative Sciences to Present at 4th Annual BIO
InvestorForum Conference
September 17,
2007
Oculus
Innovative Sciences Microcyn Technology Data to
be Presented by Researchers at the 47th Interscience
Conference on Antimicrobial Agents and Chemotherapy
September 17,
2007
Oculus
Innovative Sciences Provides Update of Phase II
Study for Microcyn® Technology in Mildly Infected
Diabetic Foot Ulcers
September 14,
2007
Oculus
Innovative Sciences to Conduct Conference Call
Update on Phase II Study of Microcyn® Technology
in Mildly Infected Diabetic Foot Ulcers
September 6, 2007
Oculus
Innovative Sciences to Present at First Albany Capital
Regenerative Technologies Conference
August 29, 2007
Oculus
Innovative Sciences to Present at Roth Capital Partners
2007 New York Conference
August 9, 2007
Oculus
Innovative Sciences Announces Fiscal First Quarter
2008 Financial Results
August 8, 2007
Oculus
Innovative Sciences Announces $10.1 Million Private
Placement of Common Stock
August 3, 2007
Oculus
Innovative Sciences Schedules Fiscal First Quarter
2008 Financial Results Release and Conference Call
June 26, 2007
Oculus
Innovative Sciences Announces Results From Anti-Inflammatory
Study Using Microcyn® Technology
June 18, 2007
Oculus
Innovative Sciences Appoints Vice President of Regulatory
Affairs and Quality
June 13, 2007
Drug
Enhancement Company of America Licenses Oculus' Microcyn®
Technology for Use in First Responder ''Pen-Like''
Applicator
June 7, 2007
Oculus
Announces Fiscal Fourth Quarter and Full Year 2007
Financial Results
June 6, 2007
Oculus
Schedules Fiscal Fourth Quarter and Full Year 2007
Financial Results Release and Conference Call
May 21, 2007
Oculus
Initiates Patient Enrollment in Phase II Study of Microcyn®
Technology for Treatment of Mild Diabetic Foot Infections
May 14, 2007
Oculus
Innovative Sciences Microcyn® Technology Presented
in Poster at European Wound Management Association
Conference
May 9, 2007
Oculus
Innovative Sciences to Present at Rodman & Renshaw
Global Healthcare Conference
April 26, 2007
China
Bao Tai, Sinopharm and Lianhua Supermarkets to Distribute
Oculus' Microcyn®-Based Wound Care Solution in
China
April 25, 2007
Oculus
Innovative Sciences, Inc. Appoints Jay E. Birnbaum
to Its Board of Directors
March 29, 2007
Oculus
Announces Initial Sites for Phase II Clinical Trial
of Microcyn® Technology in Treatment of Mild
Diabetic Foot Infections
March 13, 2007
Oculus'
Dermacyn® Wound Care Subject of 33-Patient Study
Published in International Journal of Lower Extremity
Wounds
February 22, 2007
Oculus
Innovative Sciences Announces Fiscal Third Quarter
2007 Results
January 24, 2007
Oculus
Innovative Sciences, Inc. Announces Initial Public
Offering
2006
July 5, 2006
Oculus
Innovative Sciences, Inc. Files Registration Statement
with the SEC for Proposed Initial Public Offering
2004
1 de noviembre
de 2004
Oculus
Receives Regulatory Approval To Market Dermacyn™
Wound Care in Canada. (En inglés).
24 de julio de
2004
Oculus
Lanunches First U.S. Product Formulated with Microcyn
Technology. (En inglés).
(PDF: 92 KB)
14 de mayo de 2004
Oculus Files 510(K) with FDA for Approval of Microcyn as Wound Care Dressing. (En inglés).
(PDF: 92 KB)
14 de mayo de 2004
Oculus Files Application with U.S. EPA for Approval of Microcyn as a Hospital-Grade Disinfectant. (En inglés).
(PDF: 90 KB)
1 de mayo de 2004
Oculus Closes Series "A" Round of Financing for $8 Million. (En inglés).
(PDF: 93 KB)
16 de abril de 2004
Mexican Ministry of Health Approves Microcyn Technology for Use in Veterinarian Market. (En inglés).
(PDF: 93 KB)
31 de marzo de 2004
Oculus Microcyn60 Disinfectant (OMD) Technology Receives CE Mark Approval as Disinfectant for Non-Critical Medical Devices in Europe. (En inglés).
(PDF: 94 KB)
9 de enero de 2004
Oculus Applies for CE Mark Approval for California Manufacturing Facility. (En inglés).. (Corregida el 11 de enero de 2004)
(PDF: 92 KB)
9 de enero de 2004
Microcyn Receives Approval as a Sterilant from Mexican Ministry of Health. (En inglés).
(PDF: 90 KB)
2003
19 de diciembre de 2003
Oculus Completes Incorporation of Legal Entity in the Netherlands and Prepares for Opening of European Manufacturing Facility for Microcyn Technology. (En inglés).
(PDF: 92 KB)
11 de noviembre de 2003
Oculus Innovative Sciences Launches Microcyn in Mexico. (En inglés).
(PDF: 94 KB)
1 de octubre de 2003
Oculus Files for Pre-Investigational Meeting with FDA to Review Microcyn60 Antiseptic Technology. (En inglés).
(PDF: 90 KB)
18 de septiembre de 2003
MicroMed Consulting Group Announces Strategic Partnership with Roberts Consulting & Engineering. (En inglés).
(PDF: 92 KB)
9 de septiembre de 2003
Oculus Innovative Sciences Opens European Office as Company Seeks CE Mark Approval of Microcyn60 Disinfectant and Antiseptic. (En inglés).
(PDF: 91 KB)
9 de septiembre de 2003
Jim Schutz Joins Oculus Innovative Sciences as General Counsel and Corporate Secretary. (En inglés).
(PDF: 90 KB)
2 de septiembre de 2003
Dr. Andres Gutierrez of Mexican Ministry of Health Joins Oculus Advisory Board. (En inglés).
(PDF: 91 KB)
28 de agosto de 2003
Mexico's Ministry of Health to Initiate Limited Clinical Trials of Oculus's "L3" Oncology Compound in Treatment of Cervical Cancer. (En inglés).
(PDF: 92 KB)
14 de agosto de 2003
Oculus Innovative Sciences Announces Appointment of Executive Vice President and Director of Business Development. (En inglés).
(PDF: 93 KB)
31 de julio de 03
Microcyn60 Disinfectant from Oculus Innovative Sciences Receives Mexican Ministry of Health Approval. (En inglés).
(PDF: 92 KB) |
